<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - LITHIUM SALTS</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drugClass/">Drug classes</a></li>
      </ul>

      <h1>LITHIUM SALTS</h1>

      <nav>
        <ul class="nav nav-list">

          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#treatmentCessation" data-toggle="tab">Treatment cessation</a></li>
          <li><a href="#drugsInClass" data-toggle="tab">Drugs in class</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid if possible, particularly in the first trimester (risk of teratogenicity, including cardiac abnormalities).</p>
            </section>
      </section>


      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Caution in mild to moderate impairment.</p><p>Avoid in severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Addison&#8217;s disease</li>
            <li>cardiac insufficiency</li>
            <li>dehydration</li>
            <li>family history of Brugada syndrome</li>
            <li>low sodium diets</li>
            <li>personal history of Brugada syndrome</li>
            <li>rhythm disorder</li>
            <li>untreated hypothyroidism</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>veryRare:</strong> Nystagmus,
              </p>
              <p>
                <strong>notKnown:</strong> Acneiform eruptions, alopecia, anorexia, arrhythmia, arthralgia, AV block, benign intracranial hypertension, bradycardia, cardiomyopathy, cognitive impairment, dry mouth, dysgeusia, ECG changes, electrolyte imbalance, encephalopathy, euthyroid goitre, extrapyramidal side-effects, fine tremor, gastritis, gastro-intestinal disturbances, hallucinations, hyperparathyroidism, hypersalivation, hyperthyroidism, hypothyroidism, kidney changes, leucocytosis, malaise, memory loss, myalgia, myasthenia gravis, nephrogenic diabetes insipidus, nephrotic syndrome, oedema, other skin disorders, parathyroid adenoma, peripheral neuropathy, polydipsia, psoriasis exacerbation, QT interval prolongation, Raynaud&#8217;s phenomena, renal impairment, sexual dysfunction, sinus node dysfunction, speech disorder, thyroid changes, vertigo, weight changes,
              </p>
        
        
        
            <section class="overdosageInformation">
                <h3>Signs of intoxication</h3>
              <p>Signs of intoxication require withdrawal of treatment and include increasing gastro-intestinal disturbances (vomiting, diarrhoea), visual disturbances, polyuria, muscle weakness, fine tremor increasing to coarse tremor, CNS disturbances (confusion and drowsiness increasing to lack of coordination, restlessness, stupor); abnormal reflexes, myoclonus, incontinence, hypernatraemia. With severe overdosage (serum-lithium concentration above 2&#8239;mmol/litre) seizures, cardiac arrhythmias (including sino-atrial block, bradycardia and first-degree heart block), blood pressure changes, circulatory failure, renal failure, coma and sudden death reported.</p><p>For details on the management of poisoning, see Lithium, under <xref format="dita" href="#PHP78558" type="bookmark" namespace="/treatment-summaries/emergency-treatment-of-poisoning">Emergency treatment of poisoning</xref>.</p>
            </section>
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Patients should be advised to report signs and symptoms of lithium toxicity, hypothyroidism, renal dysfunction (including polyuria and polydipsia), and benign intracranial hypertension (persistent headache and visual disturbance).</p><p>Maintain adequate fluid intake and avoid dietary changes which reduce or increase sodium intake.</p>
            </section>
            <section class="patientResources">
                <h3>Lithium treatment packs</h3>
              <p>A lithium treatment pack should be given to patients on initiation of treatment with lithium. The pack consists of a patient information booklet, lithium alert card, and a record book for tracking serum-lithium concentration. Packs may be purchased from</p><ul outputclass="organization">
            <li outputclass="organizationname">3M</li>
            <li outputclass="contactnumber">0845 610 1112</li>
            <li outputclass="emailaddress">nhsforms@mmm.uk.com</li>
            </ul>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Avoid abrupt withdrawal
          </li>
          <li>
            cardiac disease
          </li>
          <li>
            concurrent ECT (may lower seizure threshold)
          </li>
          <li>
            diuretic treatment (risk of toxicity)
          </li>
          <li>
            elderly (reduce dose)
          </li>
          <li>
            epilepsy (may lower seizure threshold)
          </li>
          <li>
            myasthenia gravis
          </li>
          <li>
            psoriasis (risk of exacerbation)
          </li>
          <li>
            QT interval prolongation
          </li>
          <li>
            review dose as necessary in diarrhoea
          </li>
          <li>
            review dose as necessary in intercurrent infection (especially if sweating profusely)
          </li>
          <li>
            review dose as necessary in vomiting
          </li>
          <li>
            surgery
          </li>
        </ul>
        <ul>
          <li>
            <p>Long-term use of lithium has been associated with thyroid disorders and mild cognitive and memory impairment. Long-term treatment should therefore be undertaken only with careful assessment of risk and benefit, and with monitoring of thyroid function every 6 months (more often if there is evidence of deterioration).</p><p>The need for continued therapy should be assessed regularly and patients should be maintained on lithium after 3&#8211;5 years only if benefit persists.</p>
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Manufacturer advises effective contraception during treatment for women of child bearing potential.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

          <h3>Therapeutic drug monitoring</h3>
        
            <section class="therapeuticDrugMonitoring">
                <h3>Serum concentrations</h3>
              <p>Lithium salts have a narrow therapeutic/toxic ratio and should therefore not be prescribed unless facilities for monitoring serum-lithium concentrations are available.</p><p>Samples should be taken 12 hours after the dose to achieve a serum-lithium concentration of 0.4&#8211;1&#8239;mmol/litre (lower end of the range for maintenance therapy and elderly patients).</p><p>A target serum-lithium concentration of 0.8&#8211;1&#8239;mmol/litre is recommended for acute episodes of mania, and for patients who have previously relapsed or have sub-syndromal symptoms. It is important to determine the optimum range for each individual patient.</p><p>Routine serum-lithium monitoring should be performed weekly after initiation and after each dose change until concentrations are stable, then every 3 months thereafter. Additional serum-lithium measurements should be made if a patient develops significant intercurrent disease or if there is a significant change in a patient&#8217;s sodium or fluid intake.</p>
            </section>
        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Renal function should be monitored at baseline and every 6 months thereafter (more often if there is evidence of deterioration or if the patient has other risk factors, such as starting ACE inhibitors, NSAIDs, or diuretics).</p>
            </section>
            <section class="patientParameters">
              <p>Assess cardiac and thyroid function before initiating, and thereafter every 6 months on stabilised regimens.</p>
            </section>
      </section>



      <section class="tab-pane" id="treatmentCessation">
        <h2>Advice regarding ceasing treatment</h2>

            <section class="treatmentCessation">
              <p>While there is no clear evidence of withdrawal or rebound psychosis, abrupt discontinuation of lithium increases the risk of relapse. If lithium is to be discontinued, the dose should be reduced gradually over a period of at least 4 weeks (preferably over a period of up to 3 months). Patients and their carers should be warned of the risk of relapse if lithium is discontinued abruptly. If lithium is stopped or is to be discontinued abruptly, consider changing therapy to an atypical antipsychotic or valproate.</p>
            </section>
      </section>








      <section class="tab-pane" id="drugsInClass">
        <h2>Drugs in the class of LITHIUM SALTS</h2>

          <ul>
            <li><a href="../drug/PHP2337.html">LITHIUM CARBONATE</a></li>
            <li><a href="../drug/PHP2344.html">LITHIUM CITRATE</a></li>
          </ul>
      </section>

    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
</body>
</html>
